-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Previous studies have shown that changing vascular angiotensin II (AngII) signals drugs can reduce the pathological changes of Alzheimer disease (AD), thereby reducing the rate of disease progression
.
Recently, experts from the Dementia Research Group of the School of Translational Health Sciences at Bristol Medical School in the United Kingdom studied whether the AngII receptor antagonist losartan can reduce the clinically diagnosed brain of mild to moderate ADcompared with placebo.
Previous studies have shown that changing vascular angiotensin II (AngII) signals drugs can reduce the pathological changes of Alzheimer disease (AD), thereby reducing the rate of disease progression
After a 4-week open-label phase of active treatment, participants were randomly assigned (1:1) to take 100 mg of losartan or a matching placebo daily for 12 months
.
Minimize the score based on age and baseline medial temporal lobe atrophy, either online or via a needle-based access service over the phone
From July 22, 2014 to May 17, 2018, 261 participants entered the open label phase
.
211 people were randomly assigned to Losartan (n=105) or placebo (n=106)
Of the 197 (93%) participants who completed the study, 171 (81%) had complete primary outcome data
Schematic diagram of the test process
The difference in total volume reduction between groups was -2.
29 ml (95% CI -6.
46 to 0.
89; P=0.
14)
.
The number of adverse events was low (22 in the Losartan group and 20 in the placebo group), and there was no difference between the treatment groups
The difference in total volume reduction between groups was -2.
In summary, the use of losartan for 12 months in patients with mild to moderate AD is well tolerated, but it has no effect on reducing the rate of brain atrophy
references:
Safety and efficacy of losartan for the reduction of brain atrophy in clinically diagnosed Alzheimer's disease (the RADAR trial): a double-blind, randomised, placebo-controlled, phase 2 trial.
Safety and efficacy of losartan for the reduction of brain atrophy in clinically diagnosed Alzheimer's disease (the RADAR trial): a double-blind, randomised, placebo-controlled, phase 2 trial.
Leave a message here
